Radiolabeling of avidin with very high specific activity for internal radiation therapy of intraperitoneally disseminated tumors.

PURPOSE For the effective internal radiation therapy of i.p. disseminated tumors, we developed avidin (Av)-dendrimer-chelate complex, which can be labeled with indium-111, emitting Auger and conversion electrons, with very high specific activity, and we studied its internalization, biodistribution, and therapeutic effect in nude mice with i.p. tumors. EXPERIMENTAL DESIGN Generation 4 dendrimer (G4) was biotinylated and conjugated with 52 1B4M chelates. (111)In-G4-bt was mixed with Av to form (111)In-G4-Av complex. (111)In-G4-Av was incubated with ovarian cancer cells (SHIN-3), and the rate of internalization of the radiolabel into SHIN-3 cells was followed. (111)In-G4-Av was i.p. injected into nude mice that had i.p. disseminated SHIN-3 tumors, and the biodistribution was determined. Nude mice bearing i.p. disseminated tumors received i.p. injection of (111)In-G4-Av (9.25 or 18.5 MBq x 2, with a 1-week interval) and were followed for the formation of malignant ascites. RESULTS Av could be labeled with (111)In with specific activity as high as 37 GBq/mg. More than 75% of the radioactivity was internalized 24 h after binding to cancer cells. (111)In-G4-Av accumulated rapidly and highly in the i.p. tumors (128.20% injected dose/gram of tissue at 2 h, 114.91% injected dose/gram of tissue at 24 h for unsaturated compound) with high tumor:background ratios. Treatment with a high dose of (111)In-G4-bt-Av was tolerable and showed dose-dependent therapeutic effect. CONCLUSIONS G4-Av complex, which could be labeled with (111)In with very high specific activity and showed efficient internalization into cancer cells and high accumulation to i.p. tumors, appears to be suitable for the internal radiation therapy of i.p. disseminated tumors using metallic radionuclides emitting Auger and conversion electrons.

[1]  R. L. Juliano,et al.  PAMAM Dendrimers as Delivery Agents for Antisense Oligonucleotides , 2004, Pharmaceutical Research.

[2]  M. Brechbiel,et al.  Micro‐MR angiography of normal and intratumoral vessels in mice using dedicated intravascular MR contrast agents with high generation of polyamidoamine dendrimer core: Reference to pharmacokinetic properties of dendrimer‐based MR contrast agents , 2001, Journal of magnetic resonance imaging : JMRI.

[3]  P. Sugarbaker Review of a personal experience in the management of carcinomatosis and sarcomatosis. , 2001, Japanese journal of clinical oncology.

[4]  K Togashi,et al.  Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  M. Brechbiel,et al.  Avidin-dendrimer-(1B4M-Gd)(254): a tumor-targeting therapeutic agent for gadolinium neutron capture therapy of intraperitoneal disseminated tumor which can be monitored by MRI. , 2001, Bioconjugate chemistry.

[6]  M. Béhé,et al.  Therapeutic advantages of Auger electron- over β-emitting radiometals or radioiodine when conjugated to internalizing antibodies , 2000, European Journal of Nuclear Medicine.

[7]  Martin W. Brechbiel,et al.  Monoclonal antibody-dendrimer conjugates enable radiolabeling of antibody with markedly high specific activity with minimal loss of immunoreactivity , 2000, European Journal of Nuclear Medicine.

[8]  J. Humm,et al.  Dosimetry of Auger-Electron-Emitting Radionuclides , 2000 .

[9]  Radioimmunotherapy of human glioma xenografts in nude mice by indium-111 labelled internalising monoclonal antibody. , 1999, European journal of cancer.

[10]  G. Griffiths,et al.  Cytotoxicity with Auger electron‐emitting radionuclides delivered by antibodies , 1999, International journal of cancer.

[11]  S. Rubin,et al.  Primary peritoneal carcinoma: a review of the literature. , 1999, Obstetrical & gynecological survey.

[12]  J. Murray,et al.  Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  H. Sakahara,et al.  The relationship of glycosylation and isoelectric point with tumor accumulation of avidin. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  M. Brechbiel,et al.  Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody. , 1999, Bioconjugate chemistry.

[15]  M. Cremonesi,et al.  Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. , 1998, British Journal of Cancer.

[16]  D. Goldenberg,et al.  Therapeutic efficacy and dose‐limiting toxicity of auger‐electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: Evaluation of 125I‐ vs. 131I‐labeled CO17‐1A in a human colorectal cancer model , 1998, International journal of cancer.

[17]  姚正生 Avidin targeting of intraperitoneal tumor xenografts(腹腔内移植腫瘍のアビジンによるターゲティング) , 1998 .

[18]  R. Juliano,et al.  Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery. , 1997, Journal of pharmaceutical sciences.

[19]  H. Sakahara,et al.  Intravenous avidin chase improved localization of radiolabeled streptavidin in intraperitoneal xenograft pretargeted with biotinylated antibody. , 1997, Nuclear medicine and biology.

[20]  J. Baker,et al.  Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. , 1996, Nucleic acids research.

[21]  J. Baker,et al.  Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[22]  S. Spencer,et al.  Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  S. Adelstein,et al.  The effects of indium-111 decay on pBR322 DNA. , 1994, Radiation research.

[24]  F. Mangili,et al.  Radioimmunoguided surgery using iodine-125-labeled biotinylated monoclonal antibodies and cold avidin. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  J. Humm,et al.  Dosimetry of Auger-electron-emitting radionuclides: report no. 3 of AAPM Nuclear Medicine Task Group No. 6. , 1994, Medical physics.

[26]  H. Sakahara,et al.  Improved clearance of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a "chase" without decreased accumulation in the target tumor. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  J. Fréchet,et al.  Functional polymers and dendrimers: reactivity, molecular architecture, and interfacial energy. , 1994, Science.

[28]  Martin W. Brechbiel,et al.  Metal-chelate-dendrimer-antibody constructs for use in radioimmunotherapy and imaging , 1994 .

[29]  R. Barth,et al.  Boron neutron capture therapy of primary and metastatic brain tumors , 1994, Molecular and chemical neuropathology.

[30]  R. Howell,et al.  Radiation spectra for Auger-electron emitting radionuclides: report No. 2 of AAPM Nuclear Medicine Task Group No. 6. , 1992, Medical physics.

[31]  V. Zurawski,et al.  Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125. , 1992, Gynecologic oncology.

[32]  L. Lopalco,et al.  Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. , 1991, Cancer research.

[33]  W. Mccaughey,et al.  Pathology of the peritoneum: a review of selected topics. , 1991, Seminars in diagnostic pathology.

[34]  William A. Goddard,et al.  Starburst Dendrimers: Molecular‐Level Control of Size, Shape, Surface Chemistry, Topology, and Flexibility from Atoms to Macroscopic Matter , 1990 .

[35]  J. Mclean,et al.  The radiation dose to cells in vitro from intracellular indium-111. , 1989, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[36]  J. Mclean,et al.  The Auger electron dosimetry of indium-111 in mammalian cells in vitro. , 1989, Radiation research.

[37]  M Monsigny,et al.  Endogenous Lectins and Drug Targeting , 1988, Annals of the New York Academy of Sciences.

[38]  R. Lotan,et al.  Lectins in Cancer Cells , 1988, Annals of the New York Academy of Sciences.

[39]  J. Gershoni,et al.  Biotin binding to avidin. Oligosaccharide side chain not required for ligand association. , 1987, The Biochemical journal.

[40]  J. Beatty,et al.  Therapy of peritoneal carcinomatosis of human colon cancer xenografts with yttrium 90-labeled anti-carcinoembryonic antigen antibody ZCE025. , 1987, Archives of surgery.

[41]  R. Lotan,et al.  Transformation‐related changes in the expression of endogenous cell lectins , 1987, International journal of cancer.

[42]  H. Gabius,et al.  Endogenous tumor lectins: overview and perspectives. , 1986, Anticancer research.

[43]  P. Stahl,et al.  Isolation and characterization of a mannose/N-acetylglucosamine/fucose-binding protein from rat liver. , 1981, The Biochemical journal.